Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
64% of large firms say GLP-1 drug coverage moderately or significantly impacted their prescription drug spending Similar to the findings on use, 43% of firms with 1,000 to 4,999 workers, and 66% of firms with 5,000 or more workers, say that covering GLP-1 agonists for weight loss had a significant impact on the health plans prescription drug spending
A complete medical, surgical, social, and family history should be obtained from patients who present with this symptom, and they should undergo a physical examination that includes a pelvic examination
"No market for the GM tomato that fights cancer - Science, News"
GLP-1 Therapies Move Into the Pharmaceutical Mainstream GLP-1 receptor agonists, led by semaglutide (Wegovy) and tirzepatide (Zepbound), have significantly changed expectations for pharmacological weight loss
Furthermore, this treatment is a great supplement to weight loss programs as it supports muscle growth and optimizes physical performance
Funding This study was supported by the Municipal Health Commission of Jiang Xi Province (202311388) and the Natural Science Foundation of Jiangxi Province (2017BAB205032)
US$ 25.30
US$ 25.14
US$ 27.48
